Article in Pharmaceutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors.
Doo Hee ShimDepartment of Microbiology and Immunology, Institute for Immunology and Immunological Diseases, Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul 03722, Republic of Korea.ORCID 0000-0002-6696-7199
Min Jung KimDepartment of Pediatrics, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin-si 16995, Republic of Korea.ORCID 0000-0002-5634-9709
Hyeon Woo ChungDepartment of Microbiology and Immunology, Institute for Immunology and Immunological Diseases, Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul 03722, Republic of Korea.ORCID 0000-0001-7679-794X
Mi Na KimDepartment of Pediatrics, Institute of Allergy, Severance Hospital, Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul 03722, Republic of Korea.ORCID 0000-0002-1675-0688
Myung Hyun SohnDepartment of Pediatrics, Institute of Allergy, Severance Hospital, Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul 03722, Republic of Korea.
Sunhee LeeCollege of Pharmacy and Yonsei Institute of Pharmaceutical Sciences, Yonsei University, Incheon 21983, Republic of Korea.
Ikyon KimCollege of Pharmacy and Yonsei Institute of Pharmaceutical Sciences, Yonsei University, Incheon 21983, Republic of Korea.ORCID 0000-0002-0849-5517
Chun Geun LeeIntercollege, Hanyang University, Seoul 04763, Republic of Korea.ORCID 0000-0002-9514-3658
Jack A EliasDepartment of Molecular Microbiology and Immunology, Brown University, Providence, RI 02903, USA.ORCID 0000-0002-3124-8557
Jeon Han ParkDepartment of Microbiology and Immunology, Institute for Immunology and Immunological Diseases, Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul 03722, Republic of Korea.
Jae Myun LeeDepartment of Microbiology and Immunology, Institute for Immunology and Immunological Diseases, Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul 03722, Republic of Korea.ORCID 0000-0002-5273-3113
Funding
Basic Science Research Program through the National Research Foundation of Korea 2019R1A6A1A03032869National Research Foundation of Korea RS-2018-NR031048National Research Foundation of Korea RS-2025-00523607
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Targeting Lysyl Oxidase-like 2: A Therapeutic Strategy for Idiopathic Pulmonary Fibrosis with a Novel Indolizine Derivative. · full record | OpenQuestion